Yonghui Su1, Yongdong Jiang2, Shanshan Sun3, Huizi Yin4, Ming Shan5, Weiyang Tao6, Xiaofeng Ge7, Da Pang8. 1. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: dr_suyh@126.com. 2. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: jiangyongdonghmu@126.com. 3. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: sunshanshandabao@163.com. 4. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: rickyyin1988@hotmail.com. 5. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: shanming@ems.hrbmu.edu.cn. 6. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: twyssw@hotmail.com. 7. Department of Radiotherapy, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: gexiaofeng121@163.com. 8. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: pangdasir@163.com.
Abstract
BACKGROUND AND PURPOSES: HER2 protein expression has been considered to be an important prognostic factor in breast cancer patients. Although the molecular mechanism of HER2 protein expression is currently unknown, single nucleotide polymorphisms (SNPs) of the HER2 gene may have some effects on its own expression. Here, we performed a trial to study the association between HER2 genetic polymorphisms and its protein expression in breast cancer. METHODS: Three SNPs in the HER2 gene were genotyped in 303 breast cancer patients using the Sequenom Mass ARRAY system. HER2 protein expression, ER, PR, P53, and Ki67 status was detected by immunohistochemistry. A Pearson's chi-square test was used to analyze the associations of the polymorphisms with its protein expression, corresponding with clinicopathological characteristics of breast cancer. RESULTS: Under the codominant model, rs1058808 and rs2517956 polymorphisms were associated with HER2 protein expression in breast cancer (p=0.007; p=0.008, respectively). For SNP rs1058808, patients with genotypes CG and GG were more likely to have high HER2 protein expression than patients with genotype CC (p=0.007). No significant associations could be found between the three SNPs and breast cancer patients' clinical stage, tumor size, histological grade, lymph node metastasis, ER, PR, Ki67 and P53 status (p>0.05). CONCLUSIONS: HER2 rs1058808 and rs2517956 polymorphisms are associated with its protein expression in breast cancer. Our study might provide new insights into the mechanisms of HER2 protein expression.
BACKGROUND AND PURPOSES: HER2 protein expression has been considered to be an important prognostic factor in breast cancerpatients. Although the molecular mechanism of HER2 protein expression is currently unknown, single nucleotide polymorphisms (SNPs) of the HER2 gene may have some effects on its own expression. Here, we performed a trial to study the association between HER2 genetic polymorphisms and its protein expression in breast cancer. METHODS: Three SNPs in the HER2 gene were genotyped in 303 breast cancerpatients using the Sequenom Mass ARRAY system. HER2 protein expression, ER, PR, P53, and Ki67 status was detected by immunohistochemistry. A Pearson's chi-square test was used to analyze the associations of the polymorphisms with its protein expression, corresponding with clinicopathological characteristics of breast cancer. RESULTS: Under the codominant model, rs1058808 and rs2517956 polymorphisms were associated with HER2 protein expression in breast cancer (p=0.007; p=0.008, respectively). For SNP rs1058808, patients with genotypes CG and GG were more likely to have high HER2 protein expression than patients with genotype CC (p=0.007). No significant associations could be found between the three SNPs and breast cancerpatients' clinical stage, tumor size, histological grade, lymph node metastasis, ER, PR, Ki67 and P53 status (p>0.05). CONCLUSIONS:HER2rs1058808 and rs2517956 polymorphisms are associated with its protein expression in breast cancer. Our study might provide new insights into the mechanisms of HER2 protein expression.
Authors: Katie M Marker; Valentina A Zavala; Tatiana Vidaurre; Paul C Lott; Jeannie Navarro Vásquez; Sandro Casavilca-Zambrano; Mónica Calderón; Julio E Abugattas; Henry L Gómez; Hugo A Fuentes; Ruddy Liendo Picoaga; Jose M Cotrina; Silvia P Neciosup; Carlos A Castañeda; Zaida Morante; Fernando Valencia; Javier Torres; Magdalena Echeverry; Mabel E Bohórquez; Guadalupe Polanco-Echeverry; Ana P Estrada-Florez; Silvia J Serrano-Gómez; Jenny A Carmona-Valencia; Isabel Alvarado-Cabrero; María Carolina Sanabria-Salas; Alejandro Velez; Jorge Donado; Sikai Song; Daniel Cherry; Lizeth I Tamayo; Scott Huntsman; Donglei Hu; Roberto Ruiz-Cordero; Ronald Balassanian; Elad Ziv; Jovanny Zabaleta; Luis Carvajal-Carmona; Laura Fejerman Journal: Cancer Res Date: 2020-04-03 Impact factor: 12.701
Authors: Yan Gao; Xiuwu Tang; Jieqin Cao; Rong Rong; Zhengmin Yu; Yang Liu; Yan Lu; Xiaowen Liu; Lei Han; Jiting Liu; Jun Zhang; Ming Xu; Fang Liu Journal: J Cancer Date: 2019-01-01 Impact factor: 4.207
Authors: Ibrahim O Alanazi; Jilani Purusottapatnam Shaik; Narasimha Reddy Parine; Nahla A Azzam; Othman Alharbi; Yousef M Hawsawi; Atif Abdulwahab A Oyouni; Osama M Al-Amer; Faisal Alzahrani; Majid A Almadi; Abdulrahman M Aljebreen; Mohammad Saud Alanazi; Zahid Khan Journal: J Oncol Date: 2021-10-21 Impact factor: 4.375
Authors: Vittoria Disciglio; Andrea Devecchi; Orazio Palumbo; Massimo Carella; Donata Penso; Massimo Milione; Giorgio Valle; Marco Alessandro Pierotti; Marco Vitellaro; Lucio Bertario; Silvana Canevari; Stefano Signoroni; Loris De Cecco Journal: Chin J Cancer Date: 2016-06-07